Skip to main content

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

(per-TOO-zoo-mab-tras-TOO-zoo-mab … HY-al-yoo-RAH-nih-days)

This page contains brief information about pertuzumab, trastuzumab, and hyaluronidase-zzxf and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Phesgo
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Pertuzumab, trastuzumab, and hyaluronidase-zzxf is approved to be given with docetaxel or other chemotherapy to treat:

Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed-dose combination of pertuzumab and trastuzumab that is given as a subcutaneous injection. It can be given in less time than pertuzumab or trastuzumab, which are given as infusions. For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for Pertuzumab and Trastuzumab.

More About Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Cancer Therapies

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: